News 
Market Data 
Discover
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
CSKH trades at less than 25% of this year’s revenues with the Company expected to be profitable – a really silly valuation. Shares, in our opinion, should trade at a minimum of one to two time revenues. At two times revs, shares should be $0.24. Additional market cap needs to be added due to the probable spin off of Carbon 612. In our opinion, these shares have been a victim of the trading environment, as a result of the debt structure. The huge supply of shares going into the market as the debt holders have convert scared the common shareholder out of their shares and potential new shareholders we unable to get a handle on what was happening. The result has been a huge supply of stock with very few buyers. This made the price crash.
CSKH is fine. I predict a bit more selling from the debt holders, but with almost all debt converted, these guys will quickly run out of shares to sell. Look for a stunning turn around in the share price of CSKH as these events unfold. These shares are a big time buy at these levels.
Reversal just beginning!
1 – CSKH’s business pipeline is very full
2 – Lots of big installations currently underway
3 – CSKH is on target to meet or beat his previously stated goal of $16M in revs for the year
4 – Big bubble of revenue coming through for Q4 and Q1
5 – Financing has really freed up in the solar industry. This is resulting in more projects coming on line.
6 – The XTRAX product recently passed certification. CSKH’s partners company, Carbon 612, which co-owns XTRAX is being spun off into a separately traded company. CSKH enjoys majority ownership of Carbon 612. Smart grid and monitoring are hot topics in the energy market and CSKH has a unique product.
7 – There are about 130mm shares outstanding placing the entire market cap at ONLY about $4mm.
An other undervalued stock with high potentials.
This came up in a search for undervalued stocks
Here all have an opportunity to post their UNDERVALUED STOCK pick and give the reasons why.
MOMO plays are always WELCOME!-Encouraged for that matter!
On Our Radar-
INOL
In an announcement today, InoLife Technologies (OTCBB: INOL) a healthcare products development and marketing company declared today that they will supply and market an exclusive metabolizing test among physicians and practitioners across the country to recognize how an individuals genetic makeup affect their body’s response to Plavix. According to the company this test will only be available to certified physicians. The FDA recently stated that Plavix must carry statutory warnings going forward because according to a study it increases the likeliness of myocardial infarction among certain genetic variations. Plavix is an extremely popular drug with sale amounts in the range of $8 Billion a year and has been branded the second best selling drug in the world that reduces the risk of heart attacks and strokes.
http://latestbusiness-news.com/popular-u-s-stocks-under-watch-slry-sons-inol-mmtc-and-aavg-11099.html
